id: fda_approved_medication_access_to_heavy_drinking_relapse_risk
name: Access to FDA-Approved Medications for Alcohol Use Disorder â†’ Heavy Drinking
  Relapse Risk
from_node:
  node_id: fda_approved_medication_access
  node_name: Access to FDA-Approved Medications for Alcohol Use Disorder
to_node:
  node_id: heavy_drinking_relapse_risk
  node_name: Heavy Drinking Relapse Risk
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: FDA-approved medications are prescribed as part of comprehensive AUD treatment'
- 'Step 2: Medications modulate neurobiological pathways involved in alcohol craving
  and reward'
- 'Step 3: Pharmacotherapy reduces physiological drive to return to heavy drinking
  patterns'
- 'Step 4: Risk of relapse to heavy drinking decreases compared to behavioral therapy
  alone'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Barbara J Mason and Charles J Heyser 2021. "Alcohol Use Disorder:
    The Role of Medication in Recovery.." *Alcohol research : current reviews*. https://doi.org/10.35946/arcr.v41.1.07'
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.676415'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: concurrent_behavioral_therapy
  direction: strengthens
  strength: strong
  description: Evidence-based behavioral therapy combined with medication produces
    greater reduction in relapse risk than either intervention alone
- name: medication_adherence_support
  direction: strengthens
  strength: moderate
  description: Structural supports for medication adherence (e.g., integrated care
    coordination, pharmacy access) enhance relapse prevention benefits
_source_file: /Users/mauriceelhelou/Library/CloudStorage/OneDrive-HarvardUniversity/New
  folder (2)/healthsystems/mechanism-bank/mechanisms/healthcare_access/fda_approved_medication_access_to_heavy_drinking_relapse_risk.yaml
_category: healthcare_access
